Oncology Pharma Inc.
Other OTCTotal Valuation
Oncology Pharma Inc. carries a market capitalization of 1.74M, placing it among publicly traded companies globally. Its enterprise value stands at 5.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.74M |
| Enterprise Value | 5.25M |
Valuation Ratios
The price-to-sales ratio is 53.19, and the price-to-book ratio stands at -0.19.
| PE Ratio | N/A |
| PS Ratio | 53.19 |
| PB Ratio | -0.19 |
| P/TBV Ratio | -11.21 |
| P/FCF Ratio | -6.51 |
| P/OCF Ratio | -6.51 |
Enterprise Valuation
| EV / Sales | 55.82 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Oncology Pharma Inc. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.09 |
| Quick Ratio | 0.09 |
| Debt / Equity | -65.02 |
| Debt / EBITDA | -0.51 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -136.29 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Oncology Pharma Inc.'s stock has gained approximately 63500% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 63500% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oncology Pharma Inc. generated 94,000.00 in revenue and converted that into -507,000.00 in net income, yielding earnings per share of -253,500.00. EBITDA reached -573,000.00, while operating income came in at -585,000.00.
| Revenue | 94,000.00 |
| Gross Profit | 65,000.00 |
| Operating Income | -585,000.00 |
| Pretax Income | N/A |
| Net Income | -507,000.00 |
| EBITDA | -573,000.00 |
| EBIT | -585,000.00 |
| Earnings Per Share (EPS) | -253,500.00 |
Balance Sheet
Oncology Pharma Inc. holds 43,000.00 in cash and equivalents against 290,000.00 in total debt, resulting in a net debt position of 247,000.00. Total book value stands at -25.83M, with working capital of -446,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 43,000.00 |
| Total Debt | 290,000.00 |
| Net Debt | 247,000.00 |
| Equity (Book Value) | -25.83M |
| Book Value Per Share | -12.91M |
| Working Capital | -446,000.00 |
Cash Flow
Oncology Pharma Inc. produced -768,000.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -768,000.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -768,000.00 |
| FCF Per Share | -384,000.00 |
Margins
Oncology Pharma Inc. operates with a gross margin of 69.15, reflecting its pricing power and cost economics. The operating margin of -622.34 and net profit margin of -539.36 provide insight into operational efficiency.
| Gross Margin | 69.15 |
| Operating Margin | -622.34 |
| Pretax Margin | N/A |
| Profit Margin | -539.36 |
| EBITDA Margin | -609.57 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.80 |
| FCF Yield | -15.36 |
Stock Splits
Oncology Pharma Inc.'s most recent stock split took place on October 9, 2020 with a 100:1 split ratio.
| Last Split Date | 10/9/2020 |
| Split Ratio | 100:1 |
Scores
Oncology Pharma Inc. posts an Altman Z-Score of -890.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -890.39 |